Update on vaccines for melanoma patients

Vincenzo Russo; Cristina Maccalli; Lorenzo Pilla; Santo Raffaele Mercuri; Elena Orsenigo; Sylvain Mukenge; Marco Bregni; Giorgio Parmiani

doi:10.1586/17469872.3.2.195

Update on vaccines for melanoma patients

Vincenzo Russo, Cristina Maccalli, Lorenzo Pilla, Santo Raffaele Mercuri, Elena Orsenigo, Sylvain Mukenge, Marco Bregni, Giorgio Parmiani

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

Vaccination against melanoma has a long history but only recently has this therapeutic approach found a reliable scientific rationale. This review summarizes and updates the knowledge on the role of the main players in the vaccination strategy against metastatic melanoma, that is, the melanoma-associated antigens recognized by T and natural killer T lymphocytes, the conditions for the immune response to develop and the mechanisms that interfere with it. A commented list of the major vaccination trials whose results have been recently, published or are ongoing is also presented. Reasons for failure and potential success are underlined to offer a balanced view of this scientifically exciting but still clinically unrewarding field of investigation.

Original language	English
Pages (from-to)	195-207
Number of pages	13
Journal	Expert Review of Dermatology
Volume	3
Issue number	2
DOIs	https://doi.org/10.1586/17469872.3.2.195
Publication status	Published - Apr 2008

Keywords

Melanoma
Melanoma vaccines
Melanoma-associated antigens
NKG2D
T lymphocytes
T-cell responses

ASJC Scopus subject areas

Dermatology

Access to Document

10.1586/17469872.3.2.195

Cite this

@article{94eab5b773f64c1d965da5595a64a4bf,

title = "Update on vaccines for melanoma patients",

abstract = "Vaccination against melanoma has a long history but only recently has this therapeutic approach found a reliable scientific rationale. This review summarizes and updates the knowledge on the role of the main players in the vaccination strategy against metastatic melanoma, that is, the melanoma-associated antigens recognized by T and natural killer T lymphocytes, the conditions for the immune response to develop and the mechanisms that interfere with it. A commented list of the major vaccination trials whose results have been recently, published or are ongoing is also presented. Reasons for failure and potential success are underlined to offer a balanced view of this scientifically exciting but still clinically unrewarding field of investigation.",

keywords = "Melanoma, Melanoma vaccines, Melanoma-associated antigens, NKG2D, T lymphocytes, T-cell responses",

author = "Vincenzo Russo and Cristina Maccalli and Lorenzo Pilla and Mercuri, {Santo Raffaele} and Elena Orsenigo and Sylvain Mukenge and Marco Bregni and Giorgio Parmiani",

year = "2008",

month = apr,

doi = "10.1586/17469872.3.2.195",

language = "English",

volume = "3",

pages = "195--207",

journal = "Expert Review of Dermatology",

issn = "1746-9872",

publisher = "Expert Reviews Ltd.",

number = "2",

}

TY - JOUR

T1 - Update on vaccines for melanoma patients

AU - Russo, Vincenzo

AU - Maccalli, Cristina

AU - Pilla, Lorenzo

AU - Mercuri, Santo Raffaele

AU - Orsenigo, Elena

AU - Mukenge, Sylvain

AU - Bregni, Marco

AU - Parmiani, Giorgio

PY - 2008/4

Y1 - 2008/4

N2 - Vaccination against melanoma has a long history but only recently has this therapeutic approach found a reliable scientific rationale. This review summarizes and updates the knowledge on the role of the main players in the vaccination strategy against metastatic melanoma, that is, the melanoma-associated antigens recognized by T and natural killer T lymphocytes, the conditions for the immune response to develop and the mechanisms that interfere with it. A commented list of the major vaccination trials whose results have been recently, published or are ongoing is also presented. Reasons for failure and potential success are underlined to offer a balanced view of this scientifically exciting but still clinically unrewarding field of investigation.

AB - Vaccination against melanoma has a long history but only recently has this therapeutic approach found a reliable scientific rationale. This review summarizes and updates the knowledge on the role of the main players in the vaccination strategy against metastatic melanoma, that is, the melanoma-associated antigens recognized by T and natural killer T lymphocytes, the conditions for the immune response to develop and the mechanisms that interfere with it. A commented list of the major vaccination trials whose results have been recently, published or are ongoing is also presented. Reasons for failure and potential success are underlined to offer a balanced view of this scientifically exciting but still clinically unrewarding field of investigation.

KW - Melanoma

KW - Melanoma vaccines

KW - Melanoma-associated antigens

KW - NKG2D

KW - T lymphocytes

KW - T-cell responses

UR - http://www.scopus.com/inward/record.url?scp=55249088315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55249088315&partnerID=8YFLogxK

U2 - 10.1586/17469872.3.2.195

DO - 10.1586/17469872.3.2.195

M3 - Article

AN - SCOPUS:55249088315

VL - 3

SP - 195

EP - 207

JO - Expert Review of Dermatology

JF - Expert Review of Dermatology

SN - 1746-9872

IS - 2

ER -

Update on vaccines for melanoma patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this